18F-FES PET/CT's Additional Clinical Value in ER+ BC
NCT04006626 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 19
Last updated 2019-07-05
Summary
To figure out whethetr 18F-FES PET/CT could influence the staging and management of newly diagnosed Oestrogen Receptor-positive Breast Cancer Patients.
Conditions
Sponsors & Collaborators
-
Fudan University
lead OTHER
Principal Investigators
-
Biyun Wang, Professor · Fudan University
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-02-15
- Primary Completion
- 2019-06-12
- Completion
- 2019-06-20
Countries
- China
Study Locations
More Related Trials
-
Negative ER Expression Assessed by 18F-FES PET/CT in the MBC With ER-positive Primary Tumor
NCT05797987 ·Status: COMPLETED
-
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
NCT03544762 ·Status: UNKNOWN ·Phase: PHASE3
-
F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy
NCT02149173 ·Status: TERMINATED ·Phase: NA
-
Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET
NCT04992156 ·Status: COMPLETED
-
Fluoroestradiol PET Imaging in Predicting Response to Hormone Therapy of Breast Cancer
NCT01627704 ·Status: COMPLETED ·Phase: NA
-
18F-fluoroestradiol (FES) PET/CT for Breast Cancer
NCT04883814 ·Status: UNKNOWN ·Phase: PHASE2
-
Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer
NCT05541367 ·Status: RECRUITING
-
Early Interim 18F-FDG-PET and 18F-FLT-PET for Predicting Treatment Response and Survival in Metastatic Breast Cancer
NCT04411966 ·Status: COMPLETED ·Phase: NA
-
Relationship Between Hypoxia and Endocrine Response in Human Breast Cancer
NCT01814449 ·Status: UNKNOWN
-
FES (16α-[18F]-Fluoro-17β-estradiol)-PET: Towards a New Standard to Stage Locally Advanced and Recurrent, Estrogen Receptor Positive (ER+) Breast Cancer? Pilot Study to Compare [18F]FES-PET and [18F]FDG-PET
NCT03726931 ·Status: COMPLETED ·Phase: NA
-
4FMFES-PET Imaging of ER+ Advanced Breast Cancers
NCT04824014 ·Status: RECRUITING ·Phase: PHASE2
-
Breast PET Feasibility
NCT03198442 ·Status: COMPLETED ·Phase: NA
-
[18F]FES PET/CT in Endocrine Refractory Breast Cancer
NCT02409316 ·Status: COMPLETED ·Phase: PHASE2
-
FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy
NCT02398773 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy
NCT04692103 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer
NCT01986569 ·Status: COMPLETED ·Phase: PHASE3
-
FES-PET for Patients Treated on NCI Protocol 8762
NCT01714128 ·Status: WITHDRAWN ·Phase: NA
-
Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer
NCT03507088 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Unconformity of the Hormonal Status of Metastatic Lesions During a First Relapse of Breast Cancer Initially Expressing Estrogen Receptors: a Pilot Study on the Interest of PET With FES
NCT03873428 ·Status: RECRUITING ·Phase: NA
-
Study on the Value of Non-invasive Dual-Pet Information in Subtype of Metastatic Breast Cancer
NCT04758416 ·Status: UNKNOWN
-
Prediction of Response to 2nd-line Hormone Therapy by FES CT/PET in Patients With Metastatic Breast Cancer
NCT03442504 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer.
NCT06335069 ·Status: RECRUITING ·Phase: PHASE2
-
PET and MRI in the Follow-up of Neoadjuvant Chemotherapy of Breast Cancer
NCT00236275 ·Status: COMPLETED ·Phase: PHASE3
-
[18F]FES PET/CT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast Cancer
NCT07314073 ·Status: RECRUITING ·Phase: PHASE2
-
18F-FSPG PET/CT Imaging in Patients With Cancers
NCT03144622 ·Status: UNKNOWN